Summit Therapeutics raises $235M

Summit Therapeutics announced that the company accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 10.35M shares of the company’s common stock at $22.70 per share, the closing price on Wednesday, September 11, 2024, for aggregate gross proceeds to the company of approximately $235M. The capital raise was completed without bankers’ fees. All of Summit’s Section 16 officers participated in the capital raise. A total of $79M was raised by insiders, including Robert Duggan, Dr. Maky Zanganeh, Manmeet Soni, and Bhaskar Anand, as well as Jeff Huber, a member of the Board of Directors, who invested via a controlled entity. The remaining $156M was raised with multiple leading biopharma institutional investors. Summit intends to use the net proceeds to advance, in part, the clinical development of ivonescimab, including in non-small cell lung cancer and in settings outside of lung cancer by leveraging the data that will be presented at ESMO, which may include, but is not limited to, colorectal cancer, and triple-negative breast cancer, in addition to working capital needs and general corporate purposes.